146 related articles for article (PubMed ID: 15277273)
1. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel A; Jahnke K; Thiel E; Keilholz U
Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
[No Abstract] [Full Text] [Related]
2. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Alimonti A; Satta F; Pavese I; Burattini E; Zoffoli V; Vecchione A
Ann Oncol; 2003 May; 14(5):805-6. PubMed ID: 12702539
[No Abstract] [Full Text] [Related]
3. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
7. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
8. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
[No Abstract] [Full Text] [Related]
9. Irinotecan and UFT/leucovorin in patients with advanced cancers.
Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504
[TBL] [Abstract][Full Text] [Related]
10. Reducing irinotecan-associated diarrhea in children.
Wagner LM; Crews KR; Stewart CF; Rodriguez-Galindo C; McNall-Knapp RY; Albritton K; Pappo AS; Furman WL
Pediatr Blood Cancer; 2008 Feb; 50(2):201-7. PubMed ID: 17570704
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Oncologic Drugs Advisory Committee
Clin Colorectal Cancer; 2002 May; 2(1):8-10. PubMed ID: 12453328
[No Abstract] [Full Text] [Related]
12. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
[No Abstract] [Full Text] [Related]
13. Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
Duffour J; Gourgou S; Seitz JF; Senesse P; Boutet O; Castera D; Kramar A; Ychou M
Anticancer Res; 2002; 22(6B):3727-31. PubMed ID: 12552984
[TBL] [Abstract][Full Text] [Related]
14. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Kehrer DF; Sparreboom A; Verweij J; de Bruijn P; Nierop CA; van de Schraaf J; Ruijgrok EJ; de Jonge MJ
Clin Cancer Res; 2001 May; 7(5):1136-41. PubMed ID: 11350876
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-induced immune thrombocytopenia.
Mirtsching BC; George JN; Aster RH; Curtis BR
Am J Med Sci; 2014 Feb; 347(2):167-9. PubMed ID: 24472819
[No Abstract] [Full Text] [Related]
16. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
17. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Lenfers BH; Loeffler TM; Droege CM; Hausamen TU
Ann Oncol; 1999 Oct; 10(10):1251-3. PubMed ID: 10586346
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
19. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
20. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
